Patents Examined by Jeanette M Lieb
  • Patent number: 10828374
    Abstract: There is no specific cure for chronic kidney disease (CKD), which affects one in every ten adults. The unmet medical need has created significant interest in regenerative therapeutic approaches. Described herein is a radically new and innovative therapeutic approach identified by characterizing a novel mechanism of renal tissue repair and its role in glomerular injury. By targeting this mechanism in CKD, significant therapeutic benefit supported by rapid cellular remodeling of kidney tissues, coincident with structural and functional nephron regeneration. Methods and compositions for achieving the described therapeutic approach are fundamentally different from existing strategies.
    Type: Grant
    Filed: November 7, 2017
    Date of Patent: November 10, 2020
    Assignee: MACULA DENSA CELL LLC
    Inventor: Janos Peti-Peterdi
  • Patent number: 10829518
    Abstract: Provided herein are compositions including peptides, pharmaceutical preparations thereof, and methods of preventing photoreceptor death therewith and protecting of retinal cells, including, but not limited to, photoreceptors and retinal pigment epithelium, from Fas- or TRAIL-mediated apoptosis.
    Type: Grant
    Filed: November 4, 2019
    Date of Patent: November 10, 2020
    Assignees: ONL THERAPEUTICS. INC., THE REGENT OF THE UNIVERSITY OF MICHIGAN
    Inventors: Cagri G. Besirli, Alexander J. Bridges, John K. Freshley, William A. Hunke, Linda L. Johnson, Francis X. Smith, Ethan Sylvain, David N. Zacks
  • Patent number: 10829520
    Abstract: Beta-hairpin peptidomimetics of the general formula (I), and pharmaceutically acceptable salts thereof, with P, T, Q, and optionally L being elements as defined in the description and the claims, have Gram-negative antimicrobial activity to e.g. inhibit the growth or to kill microorganisms such as Klebsiella pneumoniae and/or Acinetobacter baumannii and/or Escherichia coli and/or Pseudomonas aeruginosa. They can be used as medicaments to treat or prevent infections or as disinfectants for foodstuffs, cosmetics, medicaments or other nutrient-containing materials. These peptidomimetics can be manufactured by a process which is based on a mixed solid- and solution phase synthetic strategy.
    Type: Grant
    Filed: March 23, 2016
    Date of Patent: November 10, 2020
    Assignee: POLYPHOR AG
    Inventors: Daniel Obrecht, Anatol Luther, Francesca Bernardini, Peter Zbinden, Alexander Lederer
  • Patent number: 10820596
    Abstract: Compositions and methods for controlling pests are provided. The methods involve transforming organisms with a nucleic acid sequence encoding an insecticidal protein. In particular, the nucleic acid sequences are useful for preparing plants and microorganisms that possess insecticidal activity. Thus, transformed bacteria, plants, plant cells, plant tissues and seeds are provided. Compositions are insecticidal nucleic acids and proteins of bacterial species. The sequences find use in the construction of expression vectors for subsequent transformation into organisms of interest including plants, as probes for the isolation of other homologous (or partially homologous) genes. The pesticidal proteins find use in controlling, inhibiting growth or killing Lepidopteran, Coleopteran, Dipteran, fungal, Hemipteran and nematode pest populations and for producing compositions with insecticidal activity.
    Type: Grant
    Filed: September 11, 2019
    Date of Patent: November 3, 2020
    Assignee: PIONEER HI-BRED INTERNATIONAL, INC.
    Inventors: Steven D Gruver, Heather Kozy, Jessica O'Rear, Barbara Rosen, Ute Schellenberger, Jun-Zhi Wei, Weiping Xie, Xiaohong Zhong, Genhai Zhu
  • Patent number: 10822371
    Abstract: The present invention discloses a solid-phase process for the preparation of a Near Infra-Red (NIR) fluorescent probe characterized by an aza-bicycloalkane based cyclic peptide labelled with a Cy5.5 dye moiety and used in the guided surgery of tumors and pathologic regions.
    Type: Grant
    Filed: December 5, 2018
    Date of Patent: November 3, 2020
    Assignee: BRACCO IMAGING S.P.A.
    Inventors: Raphael Campanella, Anthony Clouet, Luciano Lattuada
  • Patent number: 10822377
    Abstract: In one aspect, the invention relates to substituted urea depsipeptide analogs, derivatives thereof, and related compounds, which are useful as activators the ClpP endopeptidease; synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating infectious disease using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: September 30, 2019
    Date of Patent: November 3, 2020
    Assignee: St. Jude Children's Research Hospital
    Inventors: Richard E. Lee, Ying Zhao, Liu Jiuyu
  • Patent number: 10808007
    Abstract: In one aspect, the present disclosure provides tubulysin analogs of the formula (I) wherein R1, R2, R3, R4, X1, X2, X3, and A1 are as defined herein. In another aspect, the present disclosure also provides methods of preparing the compounds disclosed herein. In another aspect, the present disclosure also provides pharmaceutical compositions and methods of use of the compounds disclosed herein.
    Type: Grant
    Filed: February 25, 2016
    Date of Patent: October 20, 2020
    Assignee: William Marsh Rice University
    Inventors: Kyriacos C. Nicolaou, Dionisios Vourloumis, Jun Yin, Rohan Erande, Debashis Mandal, Phillipp Klahn
  • Patent number: 10793594
    Abstract: Some embodiments include compounds that can inhibit the growth of bacterial and/or inhibit or reduce microbial infections caused by one or more microorganisms (e.g., Pseudomonas aeruginosa and Cryptococcus neoformans) and methods of using these compounds to treat microbial infection and outbreaks and/or to reduce the formation of biofilms. Other embodiments include synthesis of the compounds that can inhibit the growth of one or more microorganisms and/or inhibit or reduce microbial infections.
    Type: Grant
    Filed: April 19, 2018
    Date of Patent: October 6, 2020
    Assignee: Indiana University Research and Technology Corporation
    Inventors: William Leonard Scott, Martin James O'Donnell, Jack Geno Samaritoni
  • Patent number: 10786553
    Abstract: The present invention relates to improved clotting compositions for producing high quality blood serum samples for analyte testing, such as for pathology testing and other biological assays. In particular, the present invention relates to the use of prothrombin activators in combination with stabilizing agents such as colloids for producing high quality blood serum samples. The present invention also relates to associated methods for preparing clotting compositions, tubes, kits and methods of diagnosis, prognosis and monitoring for responsiveness to therapy.
    Type: Grant
    Filed: October 23, 2015
    Date of Patent: September 29, 2020
    Assignee: Q-SERA PTY LTD.
    Inventors: Paul Masci, Kong-Nan Zhao, Martin Lavin, John De Jersey, Goce Dimeski
  • Patent number: 10780144
    Abstract: The disclosure relates to methods of prophylactic and therapeutic treatments of a Pneumocystis infection (i.e., an infection caused by Pneumocystis jirovecii) in a subject by administering to the subject a compound of any of formulas (I)-(III) (e.g., a salt of Compound 1, or a neutral form thereof). The disclosure also relates to methods of inhibiting the replication of a Pneumocystis spp. The methods of the disclosure can be useful in immunocompromised subjects.
    Type: Grant
    Filed: August 1, 2019
    Date of Patent: September 22, 2020
    Assignee: Cidara Therapeutics, Inc.
    Inventors: Kenneth Bartizal, Paul Daruwala, Voon Ong, Maureen Roden, Taylor Sandison, Dirk Thye
  • Patent number: 10781431
    Abstract: Non-naturally occurring peptides are provided that act as a Src SH2 domain antagonist of cardiotonic steroids. Pharmaceutical compositions comprising the peptides are also provided along with vectors encoding the peptides. Methods of treating a Src-associated disease and reducing Src activity in a cell are further provided and include administering or contacting a cell with an effective amount of the peptide.
    Type: Grant
    Filed: April 2, 2015
    Date of Patent: September 22, 2020
    Assignee: MARSHALL UNIVERSITY RESEARCH CORPORATION
    Inventors: Zijian Xie, Moumita Banerjee
  • Patent number: 10772936
    Abstract: The present invention provides modified von Willebrand Factor molecules, methods for their preparation and uses thereof. The invention further provides pharmaceutical compositions for treating coagulation disorders.
    Type: Grant
    Filed: May 20, 2016
    Date of Patent: September 15, 2020
    Assignee: CSL BEHRING LENGNAU AG
    Inventors: Stefan Schulte, Hans-Wilhelm Beltz, Sabine Pestel, Thomas Weimer, Matthias Pelzing
  • Patent number: 10772795
    Abstract: A container storing a liquid anesthetic solution is disclosed. The container is sealed by a closure, and the liquid anesthetic solution includes an anesthetic being from 0.1% to 10% by weight of the liquid anesthetic solution, water, and a solvent. The container includes a material that is inert to the anesthetic, and the closure includes siliconized rubber, a fluoropolymer, or metal that is inert to the anesthetic. The concentration of the anesthetic in the liquid anesthetic solution stored in the container following a predetermined time period is at least 93% of a concentration of the anesthetic in the liquid anesthetic solution before the liquid anesthetic solution is stored in the container.
    Type: Grant
    Filed: March 25, 2018
    Date of Patent: September 15, 2020
    Assignee: FRESNIUS KABI USA, LLC
    Inventors: Neil P. Desai, Andrew Yang, Sherry Xiaopei Ci
  • Patent number: 10774304
    Abstract: A portable and mobile bioprocessing system and method for protein manufacturing that is compact, integrated and suited for on-demand production of any type of proteins and for delivery of the produced proteins to patients or for assay purposes. The portable system and method can also be used for efficient on-demand production of any type of protein with point-of-care delivery.
    Type: Grant
    Filed: October 23, 2019
    Date of Patent: September 15, 2020
    Assignee: UNIVERSITY OF MARYLAND, BALTIMORE COUNTY
    Inventors: Govind Rao, Yordan Kostov, Leah Tolosa, Xudong Ge, Douglas Frey, Shayan Gholipour Borhani, David Burgenson
  • Patent number: 10774039
    Abstract: The invention relates to a polypeptide comprising an amino acid having a cyclopropene group wherein said cyclopropene group is joined to the amino acid via a carbamate group. Suitably the cyclopropene group is a 1,3-disubstituted cyclopropene such as a 1,3-dimethylcyclopropene. Suitably the cyclopropene group is present as a residue of a lysine amino acid. The invention also relates to methods of making the polypeptides. The invention also relates to an amino acid comprising cyclopropene wherein said cyclopropene group is joined to the amino acid moiety via a carbamate group.
    Type: Grant
    Filed: March 10, 2015
    Date of Patent: September 15, 2020
    Assignee: United Kingdom Research and Innovation
    Inventor: Thomas Elliott
  • Patent number: 10766929
    Abstract: Polypeptides that bind to viral hemagglotinin are disclosed and methods for their use in treating or limiting influenza infection, and diagnosing influenza infection.
    Type: Grant
    Filed: March 15, 2018
    Date of Patent: September 8, 2020
    Assignee: University of Washington
    Inventors: David Baker, Aaron Arthur Chevalier, Gabriel Jacob Rocklin, Christopher David Bahl, Lance Joseph Stewart, Daniel Adriano Silva Manzano, Deborah L. Fuller, Merika Treants Koday, Jason Gilmore
  • Patent number: 10766928
    Abstract: A peptide can have a sequence of one of SEQ ID NOs: 78-91. A conformationally-constrained kinked peptide includes: a conformationally-constraining portion and a kinked portion linked to the conformationally-constraining portion that conformationally constrains the kinked portion having a peptide sequence of one of SEQ NOs: 78-97. A cell-targeting compound can include a conformationally-constrained kinked peptide having a peptide sequence of one of SEQ ID NOs: 78-97. The peptide sequence can be one of SEQ ID NOs: 78-97, or 78-91, or 92-97. A cell-targeting compound can include a conformationally-constrained kinked peptide linked to a branched linker with one branch arm linked to a specific targeting moiety and one branch arm linked to a general targeting moiety. The specific targeting moiety can be an antibody. The general targeting moiety can be a lipid or cholesterol derivative.
    Type: Grant
    Filed: April 5, 2017
    Date of Patent: September 8, 2020
    Assignee: The University of Kansas
    Inventor: Blake R. Peterson
  • Patent number: 10766926
    Abstract: Provided are a polypeptide having the activity of inhibiting autophagy in a cell, a composition for inhibiting autophagy in a cell, and particularly in a tumor cell, containing the polypeptide as an active ingredient, and a pharmaceutical composition containing the polypeptide, and more specifically, a composition for inhibiting autophagy in a cell containing a polypeptide inhibiting the control mechanism of autophagy as an active ingredient, and a pharmaceutical composition for preventing or treating a neoplastic disease or for inhibiting resistance to anticancer agents, containing the polypeptide.
    Type: Grant
    Filed: May 28, 2018
    Date of Patent: September 8, 2020
    Assignee: L-BASE CO., LTD
    Inventors: Do Yong Jeon, Chang Hoon Moon, Ji Eun Jung
  • Patent number: 10745437
    Abstract: The present invention provides means and methods for equipping a polypeptide of interest at its C-terminus with a versatile adaptor amino acid that allows the functionalization of the polypeptide of interest.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: August 18, 2020
    Assignees: LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN, FORSCHUNGSVERBUND BERLIN E.V.
    Inventors: Heinrich Leonhardt, Jonas Helma, Dominik Schumacher, Christian Hackenberger
  • Patent number: 10736936
    Abstract: Methods of treating humans or animals having various conditions are disclosed which include administering a cyclosporine component. Among the conditions treated are dry mouth syndrome, verruciform xanthoma, achlorhydria, mucous cysts, oral submucous fibrosis, oral nevi, cancer of the oral mucosa, maloplakia of the genito-urinary tract, vulvovaginitis, helicobacter pylori infection, duodenal ulcers, peptic ulcers, conditions affecting the uterus and appendicitis.
    Type: Grant
    Filed: October 3, 2016
    Date of Patent: August 11, 2020
    Assignee: ALLERGAN, INC.
    Inventors: Michael E. Stern, David Power